Last reviewed · How we verify

NCT07395414

Effect of Different Work-to-rest Ratios During Simulated Taekwondo Combat on Blood Lactate, Heart Rate and Perceptual Responses in Elite Taekwondo Athletes

Completed NA Last updated 9 February 2026
What this trial tests

NA trial testing Free combat in HIIT in 20 participants. Completed in 5 June 2023.

Timeline
5 March 2023
Primary endpoint
15 April 2023
5 June 2023

Quick facts

Lead sponsorKastamonu University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment20
Start date5 March 2023
Primary completion15 April 2023
Estimated completion5 June 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kastamonu University

Who can join

Adults 18 to 26, male only, with HIIT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized cross-over study measured physiological and perceptual responses of taekwondo athletes following a free combat and combats with different W:R ratios. This study was carried out with 4 visits. The first one included body composition measurements and familiarization to the sessions and measurements. During the rest 3 visit, athletes performed simulated combats free and with 1:2 (10 sec work and 20 sec rest), and 2:1 (20 sec work and 10 sec rest) W:R ratios. During all combat sessions, athletes heart rate (HR), blood lactate (bLA), and counter-movement jump performance (CMJ) were measured at rest and at the end of each combat. HR was also measured following each set. Athletes' rating of perceived exertion (RPE) and perceived muscle soreness (PMS) were measured immediately after each combat.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of different work-to-rest ratios during simulated taekwondo combat on blood lactate, heart rate and perceptual responses in elite taekwondo athletes: a randomized crossover trial.
    Çelebi B, Öztürk F, Taşkın HB, Ceylan B. · · 2026 · PMID 42260651 · DOI 10.1186/s13102-026-01786-7

Verify or expand the search:

Other Kastamonu University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07395414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing